Frontiers in immunology · 2026
Limited effect of surfactant protein D ablation on doxorubicin-induced intestinal toxicity in mice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rathe Mathias, von Huth Sebastian, Fazli Faisal, Burton Mark, Thomassen Mads, Jiang Pingping, Moeller Jesper B, Holmskov Uffe, Husby Steffen, Sorensen Grith L
Аннотация
INTRODUCTION: Surfactant protein (SP-D) is an anti-inflammatory host defense molecule, produced by epithelial cells and present on mucosal surfaces throughout the human and mouse body. In the present study, we investigated whether SP-D attenuates chemotherapy-induced gastrointestinal toxicity and inflammation in mice.
METHODS: SP-D knockout (KO, Sftpd -/-) mice and wild type (WT, Sftpd +/+) littermates were treated with doxorubicin (20mg/kg) or saline and sacrificed at day 3 o rat day 7, post-administration. Gastrointestinal toxicity was evaluated by weight change, citrulline levels, and histopathology. Genetic expression of genes related to chemotherapy-induced mucositis, inflammation, apoptosis, and repair of the damaged epithelium was investigated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) on jejunal and colonic samples.
RESULTS: Doxorubicin significantly reduced bodyweight, and KO mice lost significantly more weight relative to WT mice. Transcriptional analyses showed a significant SP-D-dependent increase of gasdermin genes (Gsdmc2/3 and Gsdmc4) in the small intestine. The doxorubicin challenge did not alter intestinal SP-D expression.
DISCUSSION: In conclusion, SP-D had a limited but significant impact on mouse gastrointestinal toxicity after chemotherapy-induced mucositis, which primarily involved weight loss of unknown cause and had no or limited effects on intestinal morphology and inflammation.
METHODS: SP-D knockout (KO, Sftpd -/-) mice and wild type (WT, Sftpd +/+) littermates were treated with doxorubicin (20mg/kg) or saline and sacrificed at day 3 o rat day 7, post-administration. Gastrointestinal toxicity was evaluated by weight change, citrulline levels, and histopathology. Genetic expression of genes related to chemotherapy-induced mucositis, inflammation, apoptosis, and repair of the damaged epithelium was investigated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) on jejunal and colonic samples.
RESULTS: Doxorubicin significantly reduced bodyweight, and KO mice lost significantly more weight relative to WT mice. Transcriptional analyses showed a significant SP-D-dependent increase of gasdermin genes (Gsdmc2/3 and Gsdmc4) in the small intestine. The doxorubicin challenge did not alter intestinal SP-D expression.
DISCUSSION: In conclusion, SP-D had a limited but significant impact on mouse gastrointestinal toxicity after chemotherapy-induced mucositis, which primarily involved weight loss of unknown cause and had no or limited effects on intestinal morphology and inflammation.